• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience.

作者信息

Cheson B D, Simon R

出版信息

Semin Oncol. 1987 Jun;14(2 Suppl 1):126-33.

PMID:3589688
Abstract
摘要

相似文献

1
Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience.低剂量阿糖胞苷治疗急性非淋巴细胞白血病和骨髓增生异常综合征：20年经验回顾
Semin Oncol. 1987 Jun;14(2 Suppl 1):126-33.
2
[A therapeutic trial with low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a study of 15 cases].低剂量阿糖胞苷治疗急性非淋巴细胞白血病和骨髓增生异常综合征的疗效试验：15例研究
Rinsho Ketsueki. 1988 Jan;29(1):8-13.
3
[Effectiveness of low dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes--analysis of factors influencing the duration of responses, survival and clinical effects].[低剂量阿糖胞苷治疗急性非淋巴细胞白血病和骨髓增生异常综合征的疗效——影响缓解持续时间、生存及临床疗效的因素分析]
Rinsho Ketsueki. 1987 Sep;28(9):1553-60.
4
Low-dose cytarabine in myelodysplastic syndromes and acute leukemia. A comment.低剂量阿糖胞苷治疗骨髓增生异常综合征和急性白血病。一则评论。
Acta Haematol. 1986;75(2):125-6. doi: 10.1159/000206103.
5
Low-dose Ara-C in myelodysplastic syndromes and acute nonlymphoid leukemia. Experience with seven patients.低剂量阿糖胞苷治疗骨髓增生异常综合征和急性非淋巴细胞白血病。七例患者的经验。
Haematol Blood Transfus. 1987;30:315-21. doi: 10.1007/978-3-642-71213-5_48.
6
[The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
Gan To Kagaku Ryoho. 1987 Apr;14(4):1057-62.
7
[Use of small, moderate and large doses of cytarabine (ARA-C) in the treatment of leukemia and other diseases of the hematopoietic system].[小剂量、中剂量和大剂量阿糖胞苷（ARA-C）在白血病及其他造血系统疾病治疗中的应用]
Acta Haematol Pol. 1986 Jan-Jun;17(1-2):63-70.
8
[Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):996-1003.
9
[Clinical effects of low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes].
Rinsho Ketsueki. 1991 Feb;32(2):108-14.
10
[Experiences with low-dos Ara-C in the therapy of hematological neoplasms].[低剂量阿糖胞苷治疗血液系统肿瘤的经验]
Ther Umsch. 1988 Feb;45(2):119-23.

引用本文的文献

1
Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.老年骨髓增生异常综合征：治疗选择与个体化管理
Drugs Aging. 2015 Nov;32(11):891-905. doi: 10.1007/s40266-015-0312-7.
2
Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines.阿扎胞苷敏感和耐药的SKM1髓系细胞系的表型和基因型特征
Oncotarget. 2014 Jun 30;5(12):4384-91. doi: 10.18632/oncotarget.2024.
3
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
成人原发性骨髓增生异常综合征的诊断和治疗：欧洲白血病网络的建议。
Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.
4
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.序贯 LDAC 和索拉非尼治疗不适合强化治疗的 FLT3-ITD 阳性患者的快速完全分子缓解：两例病例并文献复习。
J Hematol Oncol. 2013 Jun 11;6:39. doi: 10.1186/1756-8722-6-39.
5
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.高危骨髓增生异常综合征患者的生存期延长且耐受性改善：阿扎胞苷优于低剂量阿糖胞苷。
Br J Haematol. 2010 Apr;149(2):244-9. doi: 10.1111/j.1365-2141.2010.08082.x. Epub 2010 Feb 5.
6
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.阿扎胞苷与传统治疗方案治疗高危骨髓增生异常综合征的疗效比较：一项随机、开放标签的III期研究。
Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.
7
Biology and treatment of myelodysplastic syndromes--developments in the past decade.骨髓增生异常综合征的生物学特性与治疗——过去十年的进展
Ann Hematol. 1993 Mar;66(3):107-15. doi: 10.1007/BF01697618.
8
In vitro evidence for dose-dependent cytotoxicity as the predominant effect of low dose Ara-C on human leukemic and normal marrow cells.
Cancer Chemother Pharmacol. 1989;23(2):87-94. doi: 10.1007/BF00273523.
9
Acute myelogenous leukaemia in children.儿童急性髓系白血病
Eur J Pediatr. 1989 Feb;148(5):382-8. doi: 10.1007/BF00595892.
10
Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells.
Med Oncol Tumor Pharmacother. 1989;6(3):213-7. doi: 10.1007/BF02985193.